Protara Therapeutics, Inc.
TARA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $108,730 | $21,302 | $30,176 | $75,820 |
| - Cash | $162,798 | $39,586 | $24,127 | $35,724 |
| + Debt | $4,483 | $5,467 | $6,384 | $7,239 |
| Enterprise Value | -$49,585 | -$12,817 | $12,433 | $47,335 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$341 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$48,822 | -$43,272 | -$64,567 | -$45,398 |
| % Margin | – | – | – | – |
| Net Income | -$44,596 | -$40,420 | -$65,952 | -$47,252 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.17 | -3.57 | -5.86 | -4.2 |
| % Growth | 39.2% | 39.1% | -39.5% | – |
| Operating Cash Flow | -$35,808 | -$37,557 | -$26,457 | -$34,502 |
| Capital Expenditures | -$63 | -$45 | -$120 | -$596 |
| Free Cash Flow | -$35,871 | -$37,602 | -$26,577 | -$35,098 |